Skip to main content
. Author manuscript; available in PMC: 2012 Sep 13.
Published in final edited form as: Cancer Cell. 2011 Sep 13;20(3):357–369. doi: 10.1016/j.ccr.2011.07.016

Figure 5. In vivo ROCK inhibitor treatment of oncogene bearing mice enhances their survival and modulates MPD.

Figure 5

(A) Kaplan-Meier curves of mice transplanted with 1 × 106 32D cells bearing KITD814V through tail vein and treated with PBS (n=4) or H-1152 (n=4) at 24 hour intervals via oral gavage for 21 days.*p<0.01. (B) & (C) Reduced splenomegaly and hepatomegaly in mice treated with H-1152. Mean ± SEM. n=3, *p<0.01. (D) Kaplan-Meier curves of mice transplanted with 1 × 106 32D cells bearing FLT3N51 through tail vein and treated with PBS (n=5), H-1152 (n=5, oral gavage) or fasudil (n=5, intraperitoneal) at 24 hour intervals for 21 days. .*p<0.01. (E) & (F) Reduced splenomegaly and hepatomegaly in mice treated with H-1152 or Fasudil. Spleen and liver were harvested from transplanted mice treated with PBS (at moribund) or H-1152 or fasudil (after five weeks of prolonged survival) and weights were measured. Mean ± SD. n=4–5, *p<0.01. See also Figure S3.